Therapeutic Pipeline

Dual HIF-1/HIF-2 inhibition

The hypoxia inducible factors HIF-2 and HIF-1 play a vital role in the pathology of renal cell carcinoma. Through functional screening, Curve has identified a family of Microcycle hits that inhibit the interactions between HIF-1α and HIF-1β and between HIF-2α and HIF-1β. Curve is using these Microcycles, and the pharmacophores derived from them, as starting points for lead optimisation.

Ras-Raf inhibition

Ras proteins play a pivotal role in the growth, differentiation and survival of mammalian cells and there are number of well-known permanently activated Ras mutants that drive uncontrolled cell growth. Ras mutants have been found in 20 – 25% of all human cancers, with up to 90% in specific tumors such as pancreatic cancer. Curve is using its Microcycle platform to identify inhibitors of the protein-protein interaction between mutants of Ras and Raf, including the K-Ras mutant, G12D.

Myc-MAX inhibition

Myc is often constitutively expressed in cancer cells, leading to the expression of genes that promote uncontrolled cellular proliferation. Myc is a promising target for cancer therapy; however, direct inhibition of the Myc-MAX protein-protein interaction has been challenging. Curve is using its Microcycle platform to identify inhibitors of this high-priority cancer target.